A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
NCT ID: NCT00370513
Last Updated: 2017-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
28 participants
INTERVENTIONAL
2006-12-06
2009-04-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pazopanib Arm
Different doses of oral pazopanib once daily for the duration of the study starting on Day 1 of Treatment Period 1. Treatment continues until disease progression or withdrawl from study.
pazopanib
Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pazopanib
Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Any local therapy for tumor must have been completed at least 4 weeks prior to enrolling in study
Exclusion Criteria
* Any serious or unstable medical or psychiatric conditions
* History of metastases to central nervous system
* History of ulcer, inflammatory bowel disease or disease of the gut
* History of HIV, or uncontrolled infection
* Have had a cardiac condition or stoke during the past 6 months
* High blood pressure
* Have had a blood clot during the past 6 months
* History of bleeding blood vessels
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
San Francisco, California, United States
GSK Investigational Site
Hong Kong, , Hong Kong
GSK Investigational Site
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yau T, Chen PJ, Chan P, Curtis CM, Murphy PS, Suttle AB, Gauvin J, Hodge JP, Dar MM, Poon RT. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res. 2011 Nov 1;17(21):6914-23. doi: 10.1158/1078-0432.CCR-11-0793. Epub 2011 Aug 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VEG107200
Identifier Type: -
Identifier Source: org_study_id